

Practitioner's Docket No. MPI93-006CP1DV1ACN1DV1M

RECEIVED
APR 14 2004

PATENT & TRADEMARK OFFICE
TECH CENTER 1600/2900
APR 14 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In application of: Sundelin, Johan, et al.
Application No.: 10/643,627 Group No.: 1646
Filed: August 19, 2003 Examiner: Not yet assigned
For: RECOMBINANT C140 RECEPTOR ITS AGONISTS AND ANTAGONISTS,
AND NUCLEIC ACIDS ENCODING THE RECEPTOR

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF PREVIOUSLY RECORDED ASSIGNMENT AND
PREVIOUSLY RECORDED MERGER DOCUMENT

1. Transmitted herewith for this application are:
 - a. Previously recorded Assignment from Johan Sundelin and Robert M. Scarborough to Cor Therapeutics, Inc. in USSN 08/390,301 (4 pages);
 - b. Previously recorded merger document of Cor Therapeutics, Inc. into Millennium Pharmaceuticals, Inc. in USSN 10/127,691 (12 pages); and
 - c. Return receipt postcard.
2. These documents are being provided to evidence ownership of the above-reference application by Millennium Pharmaceuticals, Inc.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING


deposited with the United States Postal Service in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail. as "Express Mail Post Office to Addressee"
Mailing Label No.

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office


Signature

Sean Hunziker/Carolyn Willey

(type or print name of person certifying)

Date: April 1, 2004

***WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI93-006CP1DV1ACN1DV1M

3. Correspondence Address

Direct all future correspondence to:

Customer Number 30405
OR
Intellectual Property Department
MILLENNIUM PHARMACEUTICALS, INC.
40 Landsdowne Street
Cambridge, MA 02139

April 1, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By Tracy M. Sioussat

Tracy M. Sioussat
Registration No. 50,609
40 Landsdowne Street
Cambridge, MA 02139
Telephone - 617-374-7679
Facsimile - 617-551-8820

Elmwood
3-14 AV



RECEIVED

APR 14 2004




UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

MARCH 07, 1996

REID G. ADLER
MORRISON & FOERSTER
2000 PENNSYLVANIA AVENUE, N.W.
SUITE 5500
WASHINGTON, D.C. 20006-1888



100089875A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, NORTH TOWER BUILDING, SUITE 10C35, WASHINGTON, D.C. 20231.

RECORDATION DATE: 08/30/1995

REEL/FRAME: 7687/0823

NUMBER OF PAGES: 3

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

SUNDELIN, JOHAN

DOC DATE: 03/13/1995

ASSIGNOR:

SCARBOROUGH, ROBERT M.

DOC DATE: 03/10/1995

ASSIGNEE:

COR THERAPEUTICS
256 E. GRAND AVENUE
SAN FRANCISCO, CALIFORNIA 94808

SERIAL NUMBER: 08390301

FILING DATE: 01/25/1995

PATENT NUMBER:

ISSUE DATE:

TONYA LEE, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS

OCKETED

P13725

11-15-1995

U.S. DEPARTMENT OF CO.

Patent and Trademark Office

Dkt No: 2803-0006 20

Assistant Commissioner for




100089875

s or copy thereof.


1. Name of conveying party(ies):

Johan SUNDELIN and Robert M. SCARBOROUGH

Name(s) of conveying party(ies) attached? Yes No E JC10AUG
30
1995
Nature of conveyance:
Assignment

8-30-95

Security Agreement



Merger

Change of Name

Other: _____

2. Name and address of receiving party(ies):

Name: COR Therapeutics

Internal Address:

Street Address: 256 E. Grand Avenue

City: San Francisco State: CA ZIP: 94808

Additional name(s) & address(es) attached? Yes NoExecution Date: March 13, 1995 and March 10, 1995


4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: _____

A. Patent Application No.(s)

08/390,301

B. Patent No.(s)

Additional numbers attached? Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:

Reid G. Adler
 MORRISON & FOERSTER
 2000 Pennsylvania Avenue, N.W.
 Suite 5500
 Washington, D.C. 20006-1888

6. Total number of applications and patents involved: 17. Total fee (37 CFR 3.41): \$40.00 Enclosed Authorized to be charged to deposit account8. Deposit account number:
03-1952

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Reid G. Adler

Name of Person Signing
Registration No. 30,988Kate H. Munasige
Reg # 29,459

Signature

for

28 August 1995

Date

Total number of pages comprising cover sheet, attachments and document: 3

Mail documents to be recorded with required cover sheet information to:

Assistant Commissioner for Patents

Box Assignments

Washington, D.C. 20231

ASSIGNMENT

JOINT

THIS ASSIGNMENT, by Johan Sundelin and Robert M. Scarborough (hereinafter referred to as the assignors), residing at Atles Gr. 3, S-24465 Furulund, SWEDEN and 2544 Belmont Canyon Road, Belmont, CALIFORNIA 94002, respectively, witnesseth:

WHEREAS, the said assignors has invented certain new and useful improvements in RECOMBINANT C140 RECEPTOR, ITS AGONISTS AND ANTAGONISTS, AND NUCLEIC ACIDS ENCODING THE RECEPTOR set forth in an application for Letters Patent of the United States, bearing Serial No. 08/390,301 and filed on January 25, 1995; and

WHEREAS, COR Therapeutics, a corporation duly organized under and pursuant to the laws of Delaware, and having its principal place of business at 256 E. Grand Avenue, San Francisco, California 94808 (hereinafter referred to as the assignee) is desirous of acquiring the entire right, title and interest in and to said inventions and said application for Letters Patent of the United States, and in and to any Letters Patent or Patents, United States or foreign, to be obtained therefor and thereon:

NOW THEREFORE, in consideration of One Dollar (\$1.00) and other good and sufficient considerations, the receipt of which is hereby acknowledged, the said assignors have sold, assigned, transferred and set over, and by these presents do sell, assign, transfer and set over, unto the said assignee, its successors, legal representatives and assigns, the entire right, title and interest in and to the above-mentioned inventions, application for Letters Patent, and any and all Letters Patent or Patents in the United States of America and all foreign countries which may be granted therefor and thereon, and in and to any and all divisions, continuations, and continuations-in-part of said application, or reissues or extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by the said assignee, for its own use and behoof and the use and behoof of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted, as fully and entirely as the same would have been held and enjoyed by the assignors, had this sale and assignment not been made.

AND for the same consideration, the said assignors hereby covenant and agree to and with the said assignee, its successors, legal representatives and assigns, that, at the time of execution and delivery of these presents, the said assignors are the sole and lawful owner of the entire right, title and interest in and to the said inventions and the application for Letters Patent above-mentioned, and that the same are unencumbered and that the said assignors have good and full right and lawful authority to sell and convey the same in the manner herein set forth.

AND for the same consideration, the said assignors hereby covenant and agree to and with the said assignee, its successors, legal representatives and assigns, that the said assignors will, whenever counsel of the said assignee, or the counsel of its successors, legal representatives and assigns, shall advise that any proceeding in connection with said inventions, or said application for Letters Patent, or any proceeding in connection with Letters Patent for said inventions in any country, including interference proceedings, is lawful and desirable, or that any division, continuation or continuation-in-part of any application for Letters Patent or any reissue or extension of any Letters Patent, to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent for said inventions, without charge to said assignee, its successors, legal representatives and assigns, but at the cost and expense of the said assignee, its successors, legal representatives and assigns.

AND the said assignors hereby request the Commissioner of Patents to issue said Letters Patent of the United States to the said assignee as the assignee of said inventions and the Letters Patent to be issued thereon for the sole use and behoof of the said assignee, its successors, legal representatives and assigns.

Date March 13, 1995 Name of Inventor Johan Sundelin
Johan Sundelin
Johan Sundelin

Date _____ Name of Inventor _____ Robert M. Scarborough

ASSIGNMENT

JOINT

THIS ASSIGNMENT, by Johan Sundelin and Robert M. Scarborough (hereinafter referred to as the assignors), residing at Atles Gr. 3, S-24465 Furulund, SWEDEN and 2544 Belmont Canyon Road, Belmont, CALIFORNIA 94002, respectively, witnesseth:

WHEREAS, the said assignors has invented certain new and useful improvements in RECOMBINANT C140 RECEPTOR, ITS AGONISTS AND ANTAGONISTS, AND NUCLEIC ACIDS ENCODING THE RECEPTOR set forth in an application for Letters Patent of the United States, bearing Serial No. 08/390,301 and filed on January 25, 1995; and

WHEREAS, COR Therapeutics, a corporation duly organized under and pursuant to the laws of Delaware, and having its principal place of business at 256 E. Grand Avenue, San Francisco, California 94808 (hereinafter referred to as the assignee) is desirous of acquiring the entire right, title and interest in and to said inventions and said application for Letters Patent of the United States, and in and to any Letters Patent or Patents, United States or foreign, to be obtained therefor and thereon:

NOW THEREFORE, in consideration of One Dollar (\$1.00) and other good and sufficient considerations, the receipt of which is hereby acknowledged, the said assignors have sold, assigned, transferred and set over, and by these presents do sell, assign, transfer and set over, unto the said assignee, its successors, legal representatives and assigns, the entire right, title and interest in and to the above-mentioned inventions, application for Letters Patent, and any and all Letters Patent or Patents in the United States of America and all foreign countries which may be granted therefor and thereon, and in and to any and all divisions, continuations, and continuations-in-part of said application, or reissues or extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by the said assignee, for its own use and behoof and the use and behoof of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted, as fully and entirely as the same would have been held and enjoyed by the assignors, had this sale and assignment not been made.

AND for the same consideration, the said assignors hereby covenant and agree to and with the said assignee, its successors, legal representatives and assigns, that, at the time of execution and delivery of these presents, the said assignors are the sole and lawful owner of the entire right, title and interest in and to the said inventions and the application for Letters Patent above-mentioned, and that the same are unencumbered and that the said assignors have good and full right and lawful authority to sell and convey the same in the manner herein set forth.

AND for the same consideration, the said assignors hereby covenant and agree to and with the said assignee, its successors, legal representatives and assigns, that the said assignors will, whenever counsel of the said assignee, or the counsel of its successors, legal representatives and assigns, shall advise that any proceeding in connection with said inventions, or said application for Letters Patent, or any proceeding in connection with Letters Patent for said inventions in any country, including interference proceedings, is lawful and desirable, or that any division, continuation or continuation-in-part of any application for Letters Patent or any reissue or extension of any Letters Patent, to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent for said inventions, without charge to said assignee, its successors, legal representatives and assigns, but at the cost and expense of the said assignee, its successors, legal representatives and assigns.


AND the said assignors hereby request the Commissioner of Patents to issue said Letters Patent of the United States to the said assignee as the assignee of said inventions and the Letters Patent to be issued thereon for the sole use and behoof of the said assignee, its successors, legal representatives and assigns.

Date _____ Name of Inventor _____

Johan Sundelin

Date 3-10-95 Name of Inventor _____

Robert M. Scarborough



MST
PAT84

AUGUST 13, 2002


PTAS

Chief Information Officer
Washington, DC 20231
www.uspto.gov

MORGAN, LEWIS & BOCKIUS LLP
MICHAEL S. TUSCAN P.H.
1111 PENNSYLVANIA AVE., NW
WASHINGTON, D.C. 20004



102122836A



UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 06/10/2002

REEL/FRAME: 012977/0516
NUMBER OF PAGES: 7

BRIEF: MERGER (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:
COR THERAPEUTICS, INC.

DOC DATE: 02/12/2002

ASSIGNEE:
MILLENNIUM PHARMACEUTICALS, INC.
75 SIDNEY STREET
CAMBRIDGE, MASSACHUSETTS 02139

SERIAL NUMBER: 0780832944481-5002-01
PATENT NUMBER:

FILING DATE: 12/16/1991
ISSUE DATE: Abandoned

mst|mst|rjs

SERIAL NUMBER: 0847713344481-5002-04
PATENT NUMBER:

FILING DATE: 06/07/1995
ISSUE DATE: Unissued

mst|mst|rjs

SERIAL NUMBER: 0936220744481-5002-14
PATENT NUMBER:

FILING DATE: 07/28/1999
ISSUE DATE: Abandoned

SERIAL NUMBER: 0967134644481-5002-15
PATENT NUMBER:

FILING DATE: 09/27/2000
ISSUE DATE: mst|mst|rjs

AUG 19 2002

MORGAN, LEWIS & BOCKIUS LLP

DOCKETED
By Saw Date 9/11/02

SERIAL NUMBER: 07854109
PATENT NUMBER: 44481-5004

FILING DATE: 03/20/1992
ISSUE DATE: MST|MST|RJS

SERIAL NUMBER: 08475262
PATENT NUMBER: 44481-5004-02

FILING DATE: 06/07/1995
ISSUE DATE: MST|MST|RJS

SERIAL NUMBER: 09621004
PATENT NUMBER: 44481-5004-04

FILING DATE: 07/20/2000
ISSUE DATE: MST|MST|RJS

SERIAL NUMBER: 08390301
PATENT NUMBER: 44481-5006-01

FILING DATE: 01/25/1995
ISSUE DATE: MST|MST|RJS
Abandoned

SERIAL NUMBER: 08474414
PATENT NUMBER: 44481-5006-02

FILING DATE: 06/07/1995
ISSUE DATE: MST|MST|RJS
Abandoned

SERIAL NUMBER: 08486673
PATENT NUMBER: 6297026 44481-5006-06

FILING DATE: 06/07/1995
ISSUE DATE: 10/02/2001 MST|MST|RJS
C/08ed

SERIAL NUMBER: 10127691
PATENT NUMBER: 44481-5006-09

FILING DATE: 04/23/2002
ISSUE DATE: MST|MST|RJS

SERIAL NUMBER: 09035135
PATENT NUMBER: 44481-5007-04

FILING DATE: 03/05/1998
ISSUE DATE: MST|ECW|RJS
Abandoned

SERIAL NUMBER: 09801089
PATENT NUMBER: 44481-5008-02

FILING DATE: 03/08/2001
ISSUE DATE: MST|MST|RJS

SERIAL NUMBER: 09410738
PATENT NUMBER: 44481-5010-62

FILING DATE: 10/01/1999
ISSUE DATE: MST|MST|RJS
Abandoned

SERIAL NUMBER: 09947922
PATENT NUMBER: 44481-5010-03

FILING DATE: 09/07/2001
ISSUE DATE: MST|MST|RJS
Abandoned

SERIAL NUMBER: 07801795
PATENT NUMBER: 44481-5017

FILING DATE: 12/02/1991
ISSUE DATE: MST|MST|RJS
Abandoned

SERIAL NUMBER: 08253440
PATENT NUMBER: 44481-5017-01

FILING DATE: 06/07/1994
ISSUE DATE: MST|MST|RJS
Abandoned

SERIAL NUMBER: 09419076
PATENT NUMBER: 44481-5017-07

FILING DATE: 10/15/1999
ISSUE DATE: MST|MST|RJS

SERIAL NUMBER: 09585410
PATENT NUMBER: 44481-5017-05

FILING DATE: 06/02/2000
ISSUE DATE: MST|MST|RJS

SERIAL NUMBER: 08089455
PATENT NUMBER: 44481-5018

FILING DATE: 07/09/1993
ISSUE DATE: MST|ECW|RJS
Abandoned

SERIAL NUMBER: 08884571
PATENT NUMBER: 44481-5018-03

FILING DATE: 06/27/1997
ISSUE DATE: MST|ECW|RJS
Abandoned

SERIAL NUMBER: 09560814
PATENT NUMBER: 44481-5018-04

FILING DATE: 04/28/2000
ISSUE DATE: MST|ECW|RJS

SERIAL NUMBER: 09991888 44481-5025-03
PATENT NUMBER:
FILING DATE: 11/26/2001 MST|mst|rjs
ISSUE DATE:

SERIAL NUMBER: 09473716 44481-5027-01
PATENT NUMBER:
FILING DATE: 12/29/1999 MST|mst|rjk
ISSUE DATE:

SERIAL NUMBER: 09474076 44481-5028-01
PATENT NUMBER:
FILING DATE: 12/29/1999 MST|mst|rjk
ISSUE DATE:

SERIAL NUMBER: 10071223 44481-5029-02
PATENT NUMBER:
FILING DATE: 02/11/2002 MST|mst|rjk
ISSUE DATE:

SERIAL NUMBER: 08975653 44481-5039-02
PATENT NUMBER:
FILING DATE: 11/21/1997 MST|mst|rjs
ISSUE DATE:

SERIAL NUMBER: 09673302 44481-5043
PATENT NUMBER:
FILING DATE: 03/23/2001 MST|ecw|se2
ISSUE DATE:

SERIAL NUMBER: 09775803 44481-5044-01
PATENT NUMBER:
FILING DATE: 02/05/2001 MST|ecw|se2
ISSUE DATE:

SERIAL NUMBER: 09745842 44481-5053
PATENT NUMBER:
FILING DATE: 12/26/2000 MST|mst|edl
ISSUE DATE:

SERIAL NUMBER: 08948672 44481-5012
PATENT NUMBER: 6262047
FILING DATE: 10/10/1997 Transfer to
ISSUE DATE: 07/17/2001 T+T+C

SERIAL NUMBER: 09500231 44481-5015
PATENT NUMBER:
FILING DATE: 02/08/2000 Transfer to
ISSUE DATE: T+T+C

SERIAL NUMBER: 09664535 44481-5041-01
PATENT NUMBER:
FILING DATE: 09/18/2000 JAL|ecw|ecw
ISSUE DATE: ABANDONED

SERIAL NUMBER: 09663420 44481-5061
PATENT NUMBER:
FILING DATE: 09/15/2000 Transferred
ISSUE DATE: to T+T+C

SERIAL NUMBER: 10126976 44481-5041-02
PATENT NUMBER:
FILING DATE: 04/22/2002 Transferred
ISSUE DATE: to T+T+C

SERIAL NUMBER: 09226103 44481-5042
PATENT NUMBER:
FILING DATE: 01/07/1999 Transferred
ISSUE DATE: to T+T+C

SERIAL NUMBER: 09501370 44481-5045
PATENT NUMBER:
FILING DATE: 02/11/2000 Transferred
ISSUE DATE: to T+T+C

SERIAL NUMBER: 09501371 44481-5045-01
PATENT NUMBER: 6399627
FILING DATE: 02/11/2000 Transferred
ISSUE DATE: 06/04/2002 to T+T+C

SERIAL NUMBER: 09576637 44481-5046
PATENT NUMBER:
FILING DATE: 05/24/2000 Transferred
ISSUE DATE: to T+T+C

SERIAL NUMBER: 09576634 44481-5046-01
PATENT NUMBER:
FILING DATE: 05/24/2000 Transferred
ISSUE DATE: to T+T+C

SERIAL NUMBER: 09576638 44481-5047
PATENT NUMBER:

FILING DATE: 05/24/2000 Transferred to T+T+C
ISSUE DATE:

SERIAL NUMBER: 09577131 44481-5047-01
PATENT NUMBER:

FILING DATE: 05/24/2000 Transferred to T+T+C
ISSUE DATE:

SERIAL NUMBER: 09576635 44481-5048
PATENT NUMBER:

FILING DATE: 05/20/2000 Transferred to T+T+C
ISSUE DATE:

SERIAL NUMBER: 09576636 44481-5048-01
PATENT NUMBER:

FILING DATE: 05/24/2000 Transferred to T+T+C
ISSUE DATE:

SERIAL NUMBER: 09576633 44481-5049
PATENT NUMBER:

FILING DATE: 05/24/2000 Transferred to T+T+C
ISSUE DATE:

SERIAL NUMBER: 09576632 44481-5049-01
PATENT NUMBER:

FILING DATE: 05/24/2000 Transferred to T+T+C
ISSUE DATE:

SERIAL NUMBER: 09577154 44481-5049-02
PATENT NUMBER:

FILING DATE: 05/24/2000 Transferred to T+T+C
ISSUE DATE:

SERIAL NUMBER: 09636804 44481-5050
PATENT NUMBER:

FILING DATE: 08/10/2000 Transferred to T+T+C
ISSUE DATE:

SERIAL NUMBER: 09662807 44481-5051
PATENT NUMBER:

FILING DATE: 09/15/2000 Transferred to T+T+C
ISSUE DATE:

SERIAL NUMBER: 09794214 44481-5051-01
PATENT NUMBER:

FILING DATE: 02/28/2001 Transferred to T+T+C
ISSUE DATE:

SERIAL NUMBER: 09714532 44481-5052
PATENT NUMBER:

FILING DATE: 11/17/2000 Transferred to T+T+C
ISSUE DATE:

SERIAL NUMBER: 09773383 44481-5055
PATENT NUMBER:

FILING DATE: 02/01/2001 Transferred to T+T+C
ISSUE DATE:

SERIAL NUMBER: 09773372 44481-5056
PATENT NUMBER:

FILING DATE: 02/01/2001 Transferred to T+T+C
ISSUE DATE:

SERIAL NUMBER: 09773373 44481-5057
PATENT NUMBER:

FILING DATE: 02/01/2001 Transferred to T+T+C
ISSUE DATE:

SERIAL NUMBER: 09773374 44481-5058
PATENT NUMBER:

FILING DATE: 02/01/2001 Transferred to T+T+C
ISSUE DATE:

SERIAL NUMBER: 09773375 44481-5059
PATENT NUMBER:

FILING DATE: 02/01/2001 Transferred to T+T+C
ISSUE DATE:

SERIAL NUMBER: 09775812 44481-5060
PATENT NUMBER:

FILING DATE: 02/05/2001 Transferred to T+T+C
ISSUE DATE:

SERIAL NUMBER: 09920325 44481-5060-01
PATENT NUMBER:

FILING DATE: 08/02/2001 Transferred to T+T+C
ISSUE DATE:

012977/0516 PAGE 5

SERIAL NUMBER: 09816782 44481-5062
PATENT NUMBER:

SERIAL NUMBER: 09816771 44481-5063
PATENT NUMBER:

SERIAL NUMBER: 09816781 44481-5064
PATENT NUMBER:



FILING DATE: 03/26/2001 Transferred
to TTC
ISSUE DATE:

FILING DATE: 03/26/2001 Transferred to
TTC
ISSUE DATE:

FILING DATE: 03/26/2001 Transferred
to TTC
ISSUE DATE:

TARA WASHINGTON, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS

FORM PTO-1595
(Rev. 6-93)



06-14-2002



102122836

RECORDATION FOR

PATENTS ONLY

MENT OF COMMERCE
ent and Trademark Office

Attorney Docket No.: 44481-0021-US

To the Assistant Commissioner for Patents:
Please record the attached original documents or copy thereof.

ATTN: BOX ASSIGNMENT

1. Name of conveying party(ies):

COR Therapeutics, Inc.

6-10-02

2. Name and address of receiving party(ies):

Name: Millennium Pharmaceuticals, Inc.

Street Address: 75 Sidney Street
City: Cambridge State: MA
Country: US Zip: 02139

Additional name(s) of conveying party(ies) attached?

Yes No

3. Nature of conveyance:

— Assignment Merger
— Security Agreement Change of Name
Other _____

Additional name(s) & address(es) attached?

Yes No

Execution Date(s): February 12, 2002

4. Application number(s) or patent number(s):

If this document is being filed together with a new application the execution date of the application is:

A. Patent Application No.(s): 07/808,329

B. Patent No.(s)

Additional numbers attached: Yes No See attached Schedule B.

5. Name and address of party to whom correspondence concerning document should be mailed:

6. Total number of applications and patents involved: 61

Name: Michael S. Tuscan, Ph.D.
Internal Address: Customer No. 009629
Morgan, Lewis & Bockius LLP

7. Total fee (37 C.F.R. §3.41): \$2440.00

Street Address: 1111 Pennsylvania Ave., NW
City: Washington State: D.C. Zip: 20004

Enclosed

Authorized to be charged to deposit account 50-0310

8. Deposit account number: 50-0310

Attach duplicate of page if paying by deposit account

9. Statement and Signature

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Michael S. Tuscan, Ph.D., Reg. No. 43,210

Name of Person Signing

Michael S. Tuscan

06/13/2002 DBYRNE 0000040 500310 07808329

11 FL:501 2440.00 CH

June 10, 2002

Date

Total number of pages including cover sheet, attachments and documents: 8

NA/1794661.1

Schedule B, U.S. applications

Application No.	Filing Date	Title	Ref. No.
07/808,329	1991-12-16	Antithrombosis agents	44481-5002-01
08/477,133	1995-06-07	Agents affecting thrombosis and hemostasis	44481-5002-06
09/362,207	1999-07-28	Agents affecting thrombosis and hemostasis	44481-5002-14
09/671,346	2000-09-27	Agents affecting thrombosis and hemostasis	44481-5002-15
07/854,109	1992-03-20	Glycosylation-mediated inhibition of Factor X	44481-5004
08/475,262	1995-06-07	Glycosylation-mediated inhibition of Factor X	44481-5004-02
09/621,004	2000-07-20	Glycosylation-mediated inhibition of Factor X	44481-5004-04
08/390,301	1995-01-25	Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor	44481-5006-01
08/474,414	1995-06-07	Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor	44481-5006-02
08/486,673	1995-06-07	Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor	44481-5006-06
10/127,691	2002-04-23	Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor	44481-5006-09
09/035,135	1998-03-05	Process for production of inhibited forms of activated blood factors	44481-5007-04
09/801,089	2001-03-08	Modulation of integrin-mediated signal transduction	44481-5008-02
09/410,738	1999-10-01	Methods of screening for compounds that interact with human P _{2U2} purinergic receptor	44481-5010-02
09/947,922	2001-09-07	Methods of screening for compounds that interact with human P _{2U2} purinergic receptor	44481-5010-03
07/801,795	1991-12-02	Inhibitory immunoglobulin polypeptides to human PDGF beta receptor	44481-5017
08/253,440	1994-06-07	Inhibitory immunoglobulin polypeptides to human PDGF beta receptor	44481-5017-01
09/419,076	1999-10-15	Inhibitory immunoglobulin polypeptides to human PDGF beta receptor	44481-5017-04
09/585,410	2000-06-02	Inhibitory immunoglobulin polypeptides to human PDGF beta receptor	44481-5017-05
08/089,455	1993-07-09	Platelet glycoprotein V gene and uses	44481-5018
08/884,571	1997-06-27	Platelet glycoprotein V gene and uses	44481-5018-03
09/560,814	2000-04-28	Platelet glycoprotein V gene and uses	44481-5018-04

Schedule B, U.S. applications

Application No.	Filing Date	Title	Ref. No.
09/991,888	2001-11-26	Identification of Bap-1, a protein that binds to integrin and is involved in integrin-mediated signal transduction	44481-5025-03
09/473,716	1999-12-29	Polynucleotides encoding a type V adenylyl cyclase	44481-5027-01
09/474,076	1999-12-29	Cloning and characterization of a human adenylyl cyclase	44481-5028-01
10/071,223	2002-02-11	Cloning and characterization of a human adenylyl cyclase	44481-5029-02
08/975,653	1997-11-21	Modulation of interactions between myosin and integrins	44481-5039-01
09/673,302	2001-03-23	Transgenic mammals expressing mutant GP IIIa	44481-5043
09/775,803	2001-02-05	Transgenic animals having a modified glycoprotein V gene	44481-5044
09/745,842	2000-12-26	P2Y12 receptor	44481-5053
08/948,672	1997-10-10	Selective Factor Xa inhibitors	44481-5012-01
09/500,231	2000-02-08	Selective Factor Xa inhibitors	44481-5015-02
09/664,535	2000-09-18	Benzamides and related inhibitors of Factor Xa	44481-5061-99
09/663,420	2000-09-15	Benzamides and related inhibitors of Factor Xa	44481-5061
10/126,976	2002-04-22	Benzamides and related inhibitors of Factor Xa	44481-5061-02
09/226,103	1999-01-07	Platelet ADP receptor inhibitors	44481-5042
09/501,370	2000-02-11	Alkenyl and alkynyl compounds as inhibitors of Factor Xa	44481-5045
09/501,371	2000-02-11	Inhibitors of Factor Xa	44481-5045-01
09/576,637	2000-05-24	Inhibitors of Factor Xa	44481-5046
09/576,634	2000-05-24	Inhibitors of Factor Xa	44481-5046-01
09/576,638	2000-05-24	Inhibitors of Factor Xa	44481-5047
09/577,131	2000-05-24	Inhibitors of Factor Xa	44481-5047-01
09/576,635	2000-05-24	Inhibitors of Factor Xa	44481-5048
09/576,636	2000-05-24	Inhibitors of Factor Xa	44481-5048-01
09/576,633	2000-05-24	Inhibitors of Factor Xa	44481-5049
09/576,632	2000-05-24	Inhibitors of Factor Xa	44481-5049-01
09/577,154	2000-05-24	Inhibitors of Factor Xa	44481-5049-02
09/636,804	2000-08-10	Inhibitors of Factor Xa	44481-5050

Schedule B, U.S. applications

Application No.	Filing Date	Title	Ref. No.
09/662,807	2000-09-15	Inhibitors of Factor Xa	44481-5051
09/794,214	2001-02-28	Inhibitors of Factor Xa	44481-5051-01
09/714,532	2000-11-17	β -Amino acid-, aspartic acid- and diaminopropionic -based inhibitors of Factor Xa	44481-5052
09/773,383	2001-02-01	Indole and benzimidazole inhibitors of Factor Xa	44481-5055
09/773,372	2001-02-01	Indalone and benzimidazolone inhibitors of Factor Xa	44481-5056
09/773,373	2001-02-01	3,4-Dihydro-2h-benzo[1,4]oxazine inhibitors of Factor Xa	44481-5057
09/773,374	2001-02-01	2-[1H]-Quinolone and 2-[1H]-quinoxalone inhibitors of Factor Xa	44481-5058
09/773,375	2001-02-01	Bivalent phenylene inhibitors of Factor Xa	44481-5059
09/775,812	2001-02-05	Platelet ADP receptor inhibitors	44481-5060
09/920,325	2001-08-02	Platelet ADP receptor inhibitors	44481-5060-01
09/816,782	2001-03-26	Oxindole inhibitors of Factor Xa	44481-5062
09/816,771	2001-03-26	Isoquinolone inhibitors of Factor Xa	44481-5063
09/816,781	2001-03-26	Bicyclic sulfonyl amino inhibitors of Factor Xa	44481-5064

Delaware

PAGE 1

The First State

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF OWNERSHIP, WHICH MERGES:

"COR THERAPEUTICS, INC.", A DELAWARE CORPORATION,

WITH AND INTO "MILLENNIUM PHARMACEUTICALS, INC." UNDER THE NAME OF "MILLENNIUM PHARMACEUTICALS, INC.", A CORPORATION ORGANIZED AND EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED AND FILED IN THIS OFFICE THE TWELFTH DAY OF FEBRUARY, A.D. 2002, AT 6 O'CLOCK P.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.



Harriet Smith Windsor
Harriet Smith Windsor, Secretary of State

2322355 8100M

AUTHENTICATION: 1610075

020093846

DATE: 02-12-02

STATE OF DELAWARE
SECRETARY OF STATE
DIVISION OF CORPORATIONS
FILED 06:00 PM 02/12/2002
020093846 - 2322355

CERTIFICATE OF OWNERSHIP AND MERGER

MERGING

COR THERAPEUTICS, INC.
(a Delaware corporation)

INTO

MILLENNIUM PHARMACEUTICALS, INC.
(a Delaware corporation)

Millennium Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the "Corporation"), does hereby certify:

FIRST: That the Corporation was incorporated on the 13th day of January, 1993, pursuant to the General Corporation Law of the State of Delaware.

SECOND: That the Corporation owns all of the outstanding shares of each class of the stock of COR Therapeutics, Inc., a corporation incorporated on the 4th day of February, 1988 pursuant to the General Corporation Law of the State of Delaware.

THIRD: That the Board of Directors of the Corporation, by written action in lieu of a meeting dated the 4th day of February, 2002, duly adopted the following resolutions:

RESOLVED: That, pursuant to Section 253 of the Delaware General Corporation Law, the Corporation is hereby authorized to merge COR Therapeutics, Inc., a Delaware corporation which is a wholly owned subsidiary of the Corporation, into the Corporation;

RESOLVED: That the President and Secretary of the Corporation be, and each of them hereby is, authorized to execute a Certificate of Ownership and Merger with respect to the merger of COR Therapeutics, Inc. into the Corporation, cause the same to be filed with the Secretary of State of the State of Delaware and take all such other actions and to execute all such other instruments and agreements as the officer or officers so acting may deem appropriate to effect such merger;

RESOLVED: That the merger of COR Therapeutics, Inc. into the Corporation shall be effective upon the filing of a Certificate of Ownership and Merger with the Secretary of State of the State of Delaware.

IN WITNESS WHEREOF, the Corporation has caused this Certificate to be signed by its authorized officer this 12th day of February, 2002.

MILLENNIUM
PHARMACEUTICALS, INC.

By: /s/ Mark J. Levin
Title: President